Detection of Her‑2/neu expression in gastric cancer: Quantitative PCR versus immunohistochemistry

Experimental and Therapeutic Medicine

Volumn 8, Issue 5, 2014, Pages 1501-1507

  Zhu, Guang Jun ^a   Xu, Chun Wei ^b   Fang, Mei Yu ^c   Zhang, Yu Ping ^d   Li, Yang ^b  

^a The 281st Hospital of PLA   (China)

^b Beijing Military Hospital PLA   (China)

^c ZHEJIANG CANCER HOSPITAL   (China)

^d WEIFANG PEOPLE'S HOSPITAL   (China)

Author keywords

Gastric cancer; Her 2 neu; Quantitative polymerase chain reaction

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2;

ADULT; AGED; ARTICLE; CANCER STAGING; COMPARATIVE STUDY; CONTROLLED STUDY; CORRELATION ANALYSIS; DIAGNOSTIC TEST ACCURACY STUDY; DNA EXTRACTION; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE DOSAGE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; ONCOGENE NEU; POLYMERASE CHAIN REACTION; PROTEIN EXPRESSION; SCORING SYSTEM; STOMACH CANCER; TUMOR INVASION;

EID: 84907821068     PISSN: 17920981     EISSN: 17921015     Source Type: Journal    
DOI: 10.3892/etm.2014.1982     Document Type: Article

References (24)

1. Siegel R, Naishadham D and Jemal A: Cancer statistics, 2013. CA Cancer J Clin 63: 11-30, 2013.
2. Jemal A, Bray F, Center MM, et al: Global cancer statistics. CA Cancer J Clin 61: 69-90, 2011.
3. Ferlay J, Shin HR, Bray F, et al: Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 127: 2893-2917, 2010.
4. Zou XN, Duan JJ, Huangfu XM, Chen WQ and Zhao P: Analysis of stomach cancer mortality in the national retrospective sampling survey of death causes in China. Chin J Prev Med 44: 390-397, 2010 (In Chinese).
5. Arteaga C: Targeting Her1/EGFR: a molecular approach to cancer therapy. Semin Oncol 30 (Suppl 7): 3-14, 2003.
6. Park DI, Yun JW, Park JH, et al: Her-2/neu amplification is an independent prognostic factor in gastric cancer. Dig Dis Sci 51: 1371-1379, 2006.
7. Hamilton SR and Aaltonen LA (eds): World Health Organization classification of tumors. In: Pathology and Genetics of Tumours of the Digestive System. IARC Press, Lyon, France, pp265-314, 2000.
8. Ichikura T, Tomimatsu S, Uefuji K, et al: Evaluation of the New American Joint Committee on Cancer/International Union against cancer classification of lymph node metastasis from gastric carcinoma in comparison with the Japanese classification. Cancer 86: 553-558, 1999.
9. Moelans CB, van Diest PJ, Milne AN and Offerhaus GJ: Her-2/neu testing and therapy in gastroesophageal adenocarcinoma. Patholog Res Int 2011: 674182, 2010.
10. Casalini P, Iorio MV, Galmozzi E and Ménard S: Role of HER receptors family in development and differentiation. J Cell Physiol 200: 343-350, 2004.
11. Gravalos C and Jimeno A: HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target. Ann Oncol 19: 1523-1529, 2008.
12. Wolff AC, Hammond ME, Schwartz JN, et al: American Society of Clinical Oncology/College of American Pathologists: American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Arch Pathol Lab Med 131: 18-43, 2007.
13. Bang YJ, Van Cutsem E, Feyereislova A, et al: Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 376: 687-697, 2010.
14. Hayes DF, Yamauchi H, Broadwater G, et al: Cancer and Leukemia Group B: Circulating Her-2/erbB-2/c-neu (Her-2) extracellular domain as a prognostic factor in patients with metastatic breast cancer: Cancer and Leukemia Group B Study 8662. Clin Cancer Res 7: 2703-2711, 2001.
15. Tsugawa K, Yonemura Y, Hirono Y, et al: Amplification of the c-met, c-erbB-2 and epidermal growth factor receptor gene in human gastric cancers: correlation to clinical features. Oncology 55: 475-481, 1998.
16. Yonemura Y, Ninomiya I, Tsugawa K, et al: Prognostic significance of c-erbB-2 gene expression in the poorly differentiated type of adenocarcinoma of the stomach. Cancer Detect Prev 22: 139-146, 1998.
17. Yonemura Y, Ninomiya I, Yamaguchi A, et al: Evaluation of immunoreactivity for erbB-2 protein as a marker of poor short term prognosis in gastric cancer. Cancer Res 51: 1034-1038, 1991.
18. Uchino S, Tsuda H, Maruyama K, et al: Overexpression of c-erbB-2 protein in gastric cancer. Its correlation with long-term survival of patients. Cancer 72: 3179-3184, 1993.
19. Barberis M, Pellegrini C, Cannone M, et al: Quantitative PCR and Her2 testing in breast cancer: a technical and cost-effectiveness analysis. Am J Clin Pathol 129: 563-570, 2008.
20. Bossard C, Bieche I, Le Doussal V, Lidereau R and Sabourin JC: Real-time RT-PCR: a complementary method to detect Her-2 status in breast carcinoma. Anticancer Res 25: 4679-4683, 2005.
21. Tse C, Brault D, Gligorov J, et al: Evaluation of the quantitative analytical methods real-time PCR for Her-2 gene quantification and ELISA of serum Her-2 protein and comparison with fluorescence in situ hybridization and immunohistochemistry for determining Her-2 status in breast cancer patients. Clin Chem 51: 1093-1101, 2005.
22. Nistor A, Watson PH, Pettigrew N, et al: Real-time PCR complements immunohistochemistry in the determination of Her-2/neu status in breast cancer. BMC Clin Pathol 6: 2, 2006.
23. Chariyalertsak S, Purisa W and Vinyuvat S: Her-2/neu amplification determined by real-time quantitative PCR and its association with clinical outcome of breast cancer in Thailand. Asian Pac J Cancer Prev 12: 1703-1706, 2011.
24. Page K, Hava N, Ward B, et al: Detection of Her2 amplification in circulating free DNA in patients with breast cancer. Br J Cancer 104: 1342-1348, 2011.